News & Updates

The subcutaneous infliximab formulation CT-P13 appears beneficial in the maintenance treatment of patients with moderately to severely active ulcerative colitis (UC), with data from the phase III study LIBERTY-UC showing that the drug outperforms placebo in multiple endpoints.

A robust association exists between increased natriuresis and successful decongestion with acetazolamide in patients with acute decompensated heart failure (ADHF), suggests a study.

In the post hoc analysis of data from the phase III LIBERTY ASTHMA VOYAGE study, the monoclonal antibody dupilumab reduced exacerbations and improved lung function in children aged between 6 and 11 years with moderate-to-severe asthma and baseline blood eosinophil count of ≥500 cells/μL.

In the third-line treatment of patients with refractory RAS wild-type metastatic colorectal cancer (MCRC), use of panitumumab plus the standard-of-care trifluridine-tipiracil appears to prolong progression-free survival (PFS) when compared with trifluridine-tipiracil alone, according to data from a phase II study.

The herbal combination of curcumin plus QingDai (CurQD) appears beneficial to patients with active ulcerative colitis (UC), with a recent study showing that the combination induced clinical and biomarker remission.

Exposure to broad-spectrum antibiotics may put individuals at risk of developing inflammatory bowel disease (IBD), such that the greater the dose, the higher the risk, as shown in a study.

Treatment with phentermine, topiramate, or their combination appears to help children with severe, complicated obesity shed weight, according to real-world data.